Articles tagged with Ovarian Cancer
Research finds that PEA-15 protein forces ovarian cancer cells to eat themselves, leading to increased median survival time. High levels of PEA-15 are linked to improved patient outcomes and may offer a new dimension for targeting ERK in cancer therapy.
A new anti-cancer compound, BI 6727, has shown encouraging anti-tumour activity in a phase I clinical trial. The compound works by inhibiting the action of Polo-like kinase 1, leading to abnormal mitotic spindles and disrupting cell division.
Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth in ovarian cancer. High levels of TEM1 were correlated with decreased survival rates, making it a potential screening tool for early detection.
A phase III clinical trial led by UC Irvine's Dr. Bradley Monk found trabectedin to be effective in stopping ovarian cancer cell growth, with a median progression-free time of 9.2 months for those treated with the combination therapy. The treatment has hope for improved treatment of this deadly disease.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
A new combination therapy of trabectedin and pegylated liposomal doxorubicin shows clinical benefit for women with relapsed ovarian cancer. The treatment offers an alternative to traditional platinum-based regimens, providing a fresh option for those whose cancer recurs after first-line treatment.
Researchers found overexpression of TG2 in ovarian cancer to be associated with increased tumor cell growth, adhesion, resistance to chemotherapy, and lower overall survival rates. Silencing TG2 using siRNA reversed cancer progression, suggesting the protein as a novel therapeutic approach for late-stage ovarian cancer.
A Swedish study found that more than 40% of widowers were never informed about their wives' incurable cancer or received the news in the last week of her life. The study suggests room for improvement in healthcare provider communication with husbands, particularly those who did not receive information before the wife's death.
Researchers found that ovarian cancer has a distinct scent different from other cancers, which can be detected by trained dogs. Early-stage and low-grade ovarian cancers emit the same scent as advanced tumors.
A new study finds that combining symptom screening with a simple blood test can detect over 80% of women with early-stage ovarian cancer and nearly 95% with late-stage disease. This approach may lead to improved cure rates for those diagnosed at an earlier stage.
Researchers say combined PET/CT scanning can enable doctors to determine if ovarian cancer has spread without surgery, reducing unnecessary surgeries and complications. The technology showed promising results in accurately staging early-stage ovarian cancer patients.
Researchers at University of Oklahoma discovered a chemical compound that prevents cancer in lab tests, successfully stopping normal cells from turning into cancer cells and inhibiting tumor growth. The compound, SHetA2, is being developed by NCI as a cancer prevention drug to be taken daily like a multi-vitamin.
Researchers discovered glypican-3 loss induces overgrowth through Sonic Hedgehog, a growth factor stimulating cancer growth in rare disorder SGBS. This finding opens doors for novel treatments to inhibit overgrowth activity benefiting SGBS patients and GPC3-related cancer patients.
Researchers have identified and cloned ovarian cancer stem cells, which may be the source of recurrence and resistance to chemotherapy. These stem cells can replicate indefinitely and are highly resistant to conventional treatment.
Researchers at Yale University have discovered a new drug compound, NV-128, that can induce the death of ovarian cancer cells resistant to chemotherapy. The compound works by halting the activation of the mTOR protein pathway, which is associated with tumor growth and resistance to conventional therapies.
A study found two gene variants in the AKAP protein family to be linked to an elevated breast cancer risk, particularly in women from breast cancer families. These variants, located on the AKAP9 gene, were found to increase the risk by 17% and 27% respectively.
Researchers have discovered that an enzyme called MMP-2 is necessary for ovarian cancer to attach itself to new sites, and that blocking its production can slow the spread of the disease. In a mouse study, early treatment with an MMP-2 inhibitor reduced tumor growth by 68% and nearly doubled survival time.
A nationwide study in the Netherlands found that women diagnosed with early-stage ovarian cancer treated at semispecialized or specialized hospitals survived longer than those treated at general hospitals. The estimated five-year survival improved with increasing specialization of the treatment facility, from 38% to 40.3%.
Researchers found that low-grade serous carcinoma of the ovary is less sensitive to chemotherapy than more common high-grade ovarian cancers. The overall response rate was only 4% in patients with recurrent disease, and no response was observed in women with platinum-resistant disease.
Researchers have developed a new test combining biomarkers HE4 and CA 125 to assess ovarian cancer risk. The test shows high sensitivity and specificity in predicting epithelial cancer, accurately stratifying patients as high or low risk.
Researchers found advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations experience longer progression-free and overall survival rates compared to those without BRCA mutations. Additionally, a majority of women with ovarian cancer are unaware that BRCA testing is available, despite it potentially improving thei...
A University of Minnesota study has shown promising results for thalidomide as a treatment for recurrent ovarian cancer. Patients who received the combination of thalidomide and topotecan had a higher overall response rate and longer cancer-free period compared to those receiving topotecan alone.
A protein called interleukin-8 (IL-8) promotes tumor growth and angiogenesis in ovarian cancer. Researchers have identified IL-8 as a therapeutic target and tested short interfering RNA (siRNA) to silence its production, reducing tumor size by attacking its blood supply.
Researchers at Yale School of Medicine have developed a blood test that detects early stage ovarian cancer with 99% accuracy, building on previous work showing 95% effectiveness. The new platform uses six protein biomarkers instead of four, increasing specificity from 95 to 99.4%.
A new study by Memorial Sloan Kettering Cancer Center found that risk-reducing salpingo-oophorectomy (RRSO) is associated with a 72% breast cancer risk reduction in women with BRCA2 mutations, compared to 38% for BRCA1 mutation carriers. The surgery also reduced the risk of gynecologic cancer by 85% in women with a BRCA1 mutation.
A collaborative study found that oral contraceptive use reduces ovarian cancer incidence by 8 per 1000 women before age 75. Long-term use significantly lowers mortality from the disease, preventing approximately two ovarian cancers and one death per 5000 woman-years of use.
A new study found no association between current or past smoking and ovarian cancer risk. However, an inverse trend of risk was observed with total caffeine and caffeinated coffee intake, particularly in women who had never used oral contraceptives or postmenopausal hormones.
A study published in The Lancet Oncology found that high-quality pre-operative ultrasound examinations can significantly decrease the number of unnecessary major surgical operations on women with suspected ovarian cancer. Experts' accuracy rates were 95%, while routine operators' accuracy was lower. Increasing ultrasound expertise is k...
Research published in the Journal of Clinical Oncology found that Ashkenazi Jewish women with BRCA1 or BRCA2 gene mutations have a significantly longer survival rate compared to those without these mutations. After up to nine years of follow-up, carriers were 28% less likely to die from ovarian cancer.
TGFBI, an extracellular matrix protein, induces microtubule stabilization and modulates sensitivity to paclitaxel in ovarian cancer cells. The study reveals that loss of TGFBI expression can induce resistance to taxane therapy.
Researchers have made significant progress in identifying new biomarkers for epithelial ovarian cancer, which can aid in early detection and improve treatment outcomes. The study highlights the potential of these biomarkers as therapeutic and imaging targets.
A Phase II trial of a new combination therapy for patients with platinum-resistant ovarian cancer showed a 33% overall response rate, twice as high as traditional chemotherapy regimens. The therapy combines flavopiridol and cisplatin and is promising for developing more effective treatments for this disease.
Researchers found that a low-fat dietary pattern reduced the risk of ovarian cancer by 40% in healthy postmenopausal women. The study followed 48,835 women for an average of 8.1 years and found no effect during the first four years due to the slow development of preventive benefits.
A low-fat diet was associated with a reduced risk of ovarian cancer in postmenopausal women, with the greatest reduction seen in those with high fat intake before the study. The findings suggest that a low-fat dietary pattern may be beneficial in reducing cancer incidence rates.
Pertuzumab prolongs survival time for women with Stage 3 ovarian cancer, a Phase II clinical trial found. The experimental drug added weeks to the standard survival period and was well-tolerated by the body.
A new study of 24,479 Australian women found that those with high levels of physical activity were more likely to develop ovarian cancer, with a statistically significant dose-response effect. The study suggests exercise may not have the protective effects previously thought, but rather an increased risk, particularly at medium levels.
A study found that the -765G>C COX2 polymorphism increases the risk of ovarian cancer by nearly two-fold in C allele carriers and nearly three-fold in women under 53. The mutation may enhance COX-2 gene expression, inhibiting apoptosis and promoting tumour proliferation.
A laboratory study found that cranberry compounds can sensitize human ovarian cancer cells resistant to platinum drugs, potentially improving chemotherapy effectiveness. The active compounds, called 'A-type' proanthocyanidins, appear to bind and block tumor promoter proteins in ovarian cancer cells.
A Penn State research team discovered that blocking km23, a traffic cop protein, disrupts the transport of a signaling component to the nucleus, leading to reduced gene expression and cell growth. The findings may lead to diagnostic tools and earlier treatments for ovarian cancer.
Women with endometriosis face a higher risk of certain cancers, including ovarian, kidney, and thyroid cancer. However, the risk is not affected by whether or not they have given birth. Conversely, women with endometriosis are less likely to develop cervical cancer.
Recent evidence shows ovarian cancer is preceded by symptoms like gastrointestinal or urinary issues in three to four months before diagnosis. Patient groups urge women to seek medical attention for new and persistent symptoms, while experts acknowledge the need for clinical judgement and more research funding.
Researchers at the University of Edinburgh have shown that hormone therapy can prolong the life of some ovarian cancer patients by up to three years. The study found that targeted use of an anti-oestrogen drug could slow the growth and spread of disease in highly sensitive cancers.
Pazopanib demonstrated high response rates of 27% and stable disease in 46% of patients with advanced renal cell carcinoma (RCC). In ovarian cancer, pazopanib showed biological activity in 41% of evaluable patients. These findings support further investigations into pazopanib's therapeutic potential.
Preliminary results of a Phase II trial show favorable outcomes for patients with recurrent epithelial ovarian cancer treated with VEGF Trap. After one month, 85% of participants showed stable disease, while 41% continued to have stable disease after fourteen weeks.
A study published in The Lancet found that women using Hormone Replacement Therapy (HRT) in the UK are 20% more likely to develop and die from ovarian cancer. Researchers analyzed data from over 948,000 postmenopausal women and found a significant increase in ovarian cancer cases and deaths among HRT users.
Researchers develop genetically engineered mice with defects in Wnt/â-catenin and PI3K/Pten signaling pathways, leading to rapid tumor development and metastasis. The study aims to improve early detection and treatment of ovarian cancer.
Researchers at the University of Illinois Chicago found that knocking down a specific RNA-binding protein can inhibit ovarian tumor cell growth and invasiveness. The study suggests this protein could be a new target for diagnosis or treatment of ovarian and other cancers.
A recent study found that one-third of ovarian cancer patients in the US fail to receive recommended comprehensive surgical treatment. Factors associated with undertreatment include age, race, and insurance status. The study highlights the need for increased access to specialized care from gynecologic oncologists.
A case-control study found that women with no annual medical visits or pelvic examinations and those with no regular health care provider are at a higher risk of ovarian cancer. Postmenopausal women are particularly vulnerable to this increased risk.
A new study reveals that expert centers with extensive experience in managing cancer are more cost-effective over time, providing significantly longer quality-adjusted survival compared to less experienced medical centers. High-volume multidisciplinary centers also show better outcomes for ovarian cancer patients.
Researchers found that ovarian cancer cells form by using the PAX8 protein to direct adult stem cell proliferation. This discovery opens new avenues for basic research and provides a potential biomarker for detecting ovarian cancer.
A new study estimates the patient time costs associated with cancer care, finding that hospitalizations were the largest component of patient time costs in both initial year after diagnosis and last year of life. The estimated net patient time costs ranged from $271 for melanoma to $7,799 for gastric cancer.
Women with high levels of NAC-1 protein in their ovarian cancer tissue are at increased risk of rapid and fatal recurrence. Researchers suggest testing for NAC-1 may identify patients most at risk for recurrence, guiding doctors and patients to greater vigilance and extended therapy.
A new study reveals that a specific set of symptoms and their frequency/duration can distinguish early ovarian cancer from other causes, making it a potential rapid and cost-effective screening tool. The symptom index was found to be 57% sensitive for early disease and 80% sensitive for advanced cancer.
A study found that BRCA1 and BRCA2 mutations are more common in the general population than previously reported, increasing the risk of ovarian, breast, testicular, and pancreatic cancers. The study also showed that these mutations are associated with higher risks of specific types of cancer.
Research highlights the increased risk of suicide among breast cancer survivors for up to 30 years after diagnosis, as well as the association between hormone therapies and ovarian cancer risk. Additionally, high levels of circulating sex hormones may contribute to premenopausal breast cancer risk.
Women under 45 who have both ovaries removed are at higher risk of death from hormone-related cancers and neurological diseases. The risk increases with age, suggesting that oestrogen may be protective at younger ages but less important after menopause.
Researchers found radiofrequency ablation effective in achieving local control in selected patients with advanced ovarian cancer. The procedure resulted in complete necrosis in five of six patients, with no evidence of recurrence after treatment.
The National Institutes of Health has launched the first phase of The Cancer Genome Atlas (TCGA) project to study genomic changes in lung, brain, and ovarian cancers. The TCGA pilot project aims to identify key genomic alterations associated with cancer development and progression.
A new study by Mayo Clinic found that preventive ovary removal in younger women may lead to an increased risk of death from all causes, including estrogen-related cancers and diseases of the brain and cardiovascular system. The study suggests that hormone replacement therapy is crucial for these women.